Recommendations on ELISpot assay validation by the GCC

Area of Science:

• Immunology
• Biotechnology
• Regulatory Science

Background:

• Advancements in gene therapy, cell therapy, and vaccine research necessitate robust cellular immunity testing.
• Enzyme-Linked Immunospot (ELISPOT) assays are the primary method for measuring cellular immunity.
• A lack of specific regulatory guidance for developing and validating ELISPOT assays poses challenges.

Purpose of the Study:

• To provide consensus recommendations for the validation of ELISPOT assays.
• To establish a harmonized and consistent approach to ELISPOT assay validation.
• To support contract research organizations (CROs) in regulatory environments.

Main Methods:

• Development of a white paper by the Global CRO Council.
• Consensus building on essential validation parameters for ELISPOT assays.
• Defining a standardized validation framework for regulatory compliance.

Main Results:

• Identification of key validation parameters for ELISPOT assays.
• Establishment of a harmonized approach to ELISPOT assay validation.
• Guidance provided to ensure the safety and efficacy of cell-based therapies.

Conclusions:

• The white paper addresses the critical need for standardized ELISPOT assay validation.
• Harmonized validation practices will enhance the reliability of cellular immunity testing.
• This consensus supports regulatory compliance and the advancement of therapeutic development.